# Quadrant Biosciences

We develop novel, saliva based tests for Autism, COVID-19 and Parkinson's. 

## Elevator pitch
We develop epigenetic saliva biomarkers including the world's first saliva test for autism. We recently received FDA emergency use authorization for a COVID-19 saliva test, and are currently working on developing tests for Parkinson's disease, concussion, and Anorexia nervosa.

- Canonical URL: https://wefunder.com/quadrant.biosciences
- Entity ID: wefunder:company:47827
- Last updated: 2026-06-15T05:00:18Z
- Generated at: 2026-06-15T22:17:58Z

## Quick facts
- Applied our expertise in RNA analysis to co-develop FDA authorized COVID-19 saliva test with SUNY.
- Developed & commercialized world's first saliva based epigenetic test for autism spectrum disorder.
- Sales from our new saliva COVID-19 tests have exceeded $6.5MM to date since September 2020.
- We are working with NY State to test municipalities' wastewater for COVID-19.
- Working with SUNY on pooled saliva surveillance of returning college students for COVID-19.
- Development of Parkinson's disease, concussion, and Anorexia Nervosa, diagnostic tools in progress.
- Our company is led by a former Chairman & CEO of Morgan Stanley Bank, Richard Uhlig.

## Active fundraises
- wefunder:fundraise:37723: 4(a)(6) successful (USD)
- wefunder:fundraise:28398: RegA+ successful (USD)

## Story
Leaders in the Development of Epigenetic Diagnostic ToolsQuadrant Biosciences is a life science company working with universities across the US to develop and commercialize epigenetic diagnostic solutions for autism spectrum disorder, Parkinson’s disease, and mild traumatic brain injury (concussion). Working closely with medical researchers such as SUNY Upstate Medical University and Penn State College of Medicine, we have developed a novel, saliva-based diagnostic platform called Clarifi®.In December 2019 we launched Clarifi ASD®, the world's first saliva test for autism spectrum disorder. The test, intended for children 18 months through six years of age, provides a probability of an autism diagnosis based on epigenetic markers in the saliva.Then the COVID-19 pandemic happened.Not long after we began to introduce Clarifi ASD to pediatric health care providers, the world was besieged by the COVID-19 pandemic. Our ability to access healthcare providers and share the scientific and practical utility Clarifi ASD provides to parents and physicians was greatly restricted by social distancing mandates and virus concerns which, in turn, limited our sales team’s ability to affect sales and increased commercial demand for Clarifi ASD. As a result, our sales of the Clarifi ASD test have been below expectations.So, we adapted!In response to the COVID pandemic, we immediately reduced our operating costs and, given our existing experience with RNA analysis - and the fact that COVID-19 is an RNA virus - we made the decision to pivot and work with our university partners to develop diagnostic tools for COVID-19. As a result, today we are involved in three significant, complementary COVID-19 projects to aid in the detection of COVID-19 in individuals and communities across the U.S.Watch this brief overview video of our company projects:Three Levels of Testing: A Comprehensive Approach to Assessing COVID-191. Individual Testing - Clarifi COVID-19 Test KitThe development of an individual saliva test for COVID-19 was a natural extension of our earlier work with Clarifi ASD®, which used a similar saliva collection methodology. Working in partnership with SUNY Upstate Medical University, we developed the "Clarifi COVID-19 Test Kit by SUNY Upstate Medical and Quadrant Biosciences," a non-invasive and easy to administer swab that collects saliva which is then analyzed to determine the presence or absence of the SARS-CoV-2 virus. On September 22nd, we received Emergency Use Authorization (EUA) for the Clarifi COVID-19 Test Kit!The Clarifi COVID-19 Test Kit contains the saliva collection swab and the reagents needed to run the analysis and is available for use by high-complexity clinical laboratories serving patients through physicians' offices, urgent care clinics, and hospitals.2. Community/Municipal Screening: Wastewater SurveillanceThis project, funded by New York State, involves our collaboration with SUNY ESF, Upstate Medical University, Syracuse University, and global civil engineering firm Arcadis, to collect and analyze wastewater from the county and municipal sewer systems for the presence of the COVID-19 virus. Our analysis of wastewater samples provides local health officials and policymakers with early indications and information regarding the presence and preponderance of COVID-19 infections in these communities./3cb63078d5“This can be a real game-changer in the detection and monitoring of COVID-19. Information from this testing will allow municipalities to estimate COVID-19 transmission in real time, provide instant feedback on social distancing and reopening phases, help predict hospitalizations and provide confidence for locations with zero transmission to resume normal activity.”Richard Uhlig, Founder and CEO of Quadrant BiosciencesBecause this allows for large regions to be effectively tested for the presence of the COVID-19 virus, it provides a cost-effective and efficient way to screen residents in towns, cities, states, and universities, even in the absence of individual testing.3. Group/College Testing: Pooled TestingFinally, in response to an overwhelming need to efficiently test university students prior to attending classes, we have partnered with the Upstate Medical University to conduct pooled testing services for over 450,000 students preparing to begin the fall semester at SUNY schools.Each of these pooled tests for COVID-19 involves a single test of saliva samples collected from a group of 12 students. A negative test result means that all 12 students are presumed to be coronavirus-free. A positive test for the pool would mean every student in that group would need to be individually tested. Performing single tests of groups of students greatly reduces the cost of supplies, staffing, and time required to perform and interpret tests./71e98f83da"SUNY Upstate Medical University's work with Quadrant Biosciences, a Start-Up New York company, has led to important breakthroughs in the development of saliva-based diagnostic solutions for neurological conditions such as autism spectrum disorder, Parkinson's disease and concussion injuries. The ability to transfer this innovative approach to assist colleges and universities with the unprecedented and complex work of preparing for the return of students to campuses across the state is an important part of New York's response to the COVID pandemic."Dr Mantosh Dewan, Interim President, SUNY Upstate Medical UniversityDisclaimers: *On September 22, 2020, The Clarifi COVID-19 Test Kit obtained Emergency User Authorization (EUA) by the Food and Drug Administration (FDA) to be used for the diagnosis fo SARS-CoV-2. The Clarifi COVID-19 test Letter of Authorization, along with the authorization Fact Sheet for Healthcare Providers, the authorized Fact Sheet for Patients and authorized labeling are available on the FDA website.The Clarifi COVID-19 Test Kit has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. Clarifi COVID-19 has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.Despite the fact that we have the expertise, capability, and customer demand for these COVID-19 tests, the supplies needed to perform quantitative PCR are becoming increasingly difficult to obtain. This, and supply chain disruptions generally throughout the industry, could impair our ability to successfully commercialize one or all of these tests.But, we are still very much an Epigenetics Diagnostic Company!The Clarifi ASD® Test - A Game-Changer for Autism DiagnosticsWe continue to maintain a focus on our core mission to develop epigenetic diagnostic tools, such as Clarifi ASD®, the world's first saliva test for autism spectrum disorder.What is it?Clarifi ASD is a saliva test that indicates the probability that a child has autism spectrum disorder.Who is it for?Clarifi ASD is being used primarily by pediatricians and family physicians with patients (18 months through 6 years of age) with a positive autism screening test or a clinical suspicion to aid in a formal diagnosis.Why is it needed?With 1 in 54 children being diagnosed with autism in the US according to the CDC, it is one of the most commonly diagnosed developmental disabilities in the country. Unfortunately, the current diagnostic process involves long wait times, largely the result of a small number of trained clinicians to administer behavioral tests. This, in turn, leads to delays in children receiving critical intervention services. If autism is identified and treatment is initiated early, the trajectory of a child's life can be positively changed.How Clarifi ASD Can Make a DifferenceFor the first time, clinicians have an accurate biological tool to aid in the early diagnosis of autism. With this simple saliva test, Clarifi ASD can:~ Help start services earlier when treatment is most effective~ Provide specialists biological data to support their behavioral assessments~ Facilitate cost savings through improving the diagnostic process"What we’ve been able to do over the last 7 years, working together with a very dedicated team, is develop a test that utilizes saliva and can accurately distinguish whether a child has autism spectrum disorder or does not. This relies on a new type of molecular analysis that wasn't even possible until recently."Frank Middleton, Ph.D. Associate Professor of Neuroscience and Physiology, Biochemistry and Molecular Biology, Pediatrics, and Psychiatry and Behavioral Sciences.When was it launched?Clarifi ASD was launched commercially in the US in 49 states (excluding New York), in December 2019.Watch a short video about Clarifi ASD here:Who we areQuadrant Biosciences Inc was started in 2015 by Founder and CEO Rich Uhlig, and we have since grown to over 40 employees. Our team has a shared passion in being a part of positive changes in healthcare. “As a company, we are committed to looking outside ourselves, and deploying our resources to assist other organizations and research efforts dedicated to improving the lives of people with autism and their families.”Richard Uhlig, Founder and CEO, Quadrant BiosciencesCapital Raised to DateAs of January 2020, we have raised over $30 million in previous financing rounds from private investors who have recognized the value in how we intend to change the landscape of diagnostics in the future.Research Grants Received To DateWe have received numerous grants to support our research efforts.*(*The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.)Quadrant Biosciences in the MediaOur company has been featured many times in national news and scientific media outlets regarding our research and technology accomplishments in the areas of autism, concussion, and Parkinson's disease.Clarifi ASD is just the Beginning! Future products in the works.One of the most exciting things that we’ve discovered is that our Clarifi epigenetic diagnostic platform has applications for many other health issues. Diagnostic solutions for early-stage Parkinson's disease, mTBI/concussion, anorexia, and schizophrenia are currently in development. Several peer-reviewed research papers have already been published on the application of this approach to these worldwide neurological health concerns.We have numerous peer-reviewed publications supporting our scienceTo date, there have been 18 peer-reviewed papers published supporting our development of epigenetic biomarkers for autism, mild traumatic brain jury, Parkinson's disease, anorexia nervosa, and Pantothenate kinase-associated neurodegeneration disease (PKAN). These have been published in a variety of scientific journals including JAMA Pediatrics, Frontiers in Genetics, Journal of Neurotrauma, Journal of Oral Microbiology, Journal of Experimental Neuroscience, and Autism Research.Research PartnershipsWe are honored to partner with a number of outstanding research universities and organizations to help further the understanding of epigenetics.International Research PartnershipsWe also actively partnered with several international research organizations:European Autism Interventions, A Multicentre Study for Developing New Medications (EU-AIMS) - first Europe-wide collaboration between organizations with the goal of identifying markers of autism that would help in earlier and more accurate diagnosis, prognosis, and the development with new therapiesComprehensive Care Center for Disability (CAID) - centers in Santiago, San Juan, Higuey and Santo Domingo, the Dominican Republic dedicated to the evaluation, diagnosis and rehabilitation of children from zero to ten years with Autism Spectrum Disorder.Our Clinical Advisory BoardOur clinical advisory board comprises some of the leading autism and epigenetic researchers and clinicians. It is our privilege to work alongside these luminaries in the field to help families and children with autism.Want to learn more?For more information about the company, download the investor deck and visit Quadrant Biosciences www.quadrantbiosciences.com; for more information about Clarifi ASD visit www.clarifiasd.com.

## FAQ
1. **Is this fund raising under Regulation A or Title III?**
   - Hello Ram, Quadrant Biosciences is offering this as a Reg A. Thanks, The Quadrant Team
2. **Hi, Your max raise goal is $15M and you stated "Quadrant Biosciences Inc is not conducting a Regulation Crowdfunding offering." So this is a Reg D offering? Please clarify. Thanks.**
   - Hello Helen, The Quadrant Team, along with the fine people at Wefunder, has spent countless hours reviewing these pages to make sure nothing has slipped through. That being said, the above stated quote, "Quadrant Biosciences Inc is not conducting a Regulation Crowdfunding offering" has been removed from the webpage. We are conducting a Reg A offering. Thank you for pointing this out to us and please accept our apologies. We hope to see you as an investor, The Quadrant Team
3. **What valuation was given to the company in the latest funding round in Dec19?**
   - Hello William, The valuation of the company following our last Regulation D common stock offering (December 2019) was approximately $222 Million. Please note that the shares purchased in the Regulation D offering in December are subject to 1 year holding period which is a significant liquidity restriction whereas the shares purchased through this Regulation A offering are freely transferable. We hope this explanation is helpful and that you choose to join us as an investor! Thanks, The Quadra...
4. **What's the science behind testing for autism and other disease states that are primarily diagnosed through behavioral patterns?**
   - Thank you for asking! This is game-changing technology which has been developed over the past 5 years by SUNY Upstate Medical University, the Penn State College of Medicine and Quadrant Biosciences. A quick video about our science is available here: https://vimeo.com/367101683 . Further, we’ve made a commitment to transparency in our work – our 7 peer-reviewed publications related to Autism Spectrum Disorder are available here: https://www.clarifiasd.com/our-science/ (but if you only have tim...
5. **Hello ,is there any plan for future exit ( acquisition or going Public)?**
   - This is a very savvy question – thank you. As you can likely intuit, this offering presages our intended public listing. As you may know, many of the requirements to offer securities in this Regulation A offering conform to the high standards of a public offering (i.e. financial statements audited by a PCAOB certified accounting firm); this offering will help us achieve other listing requirements as well (i.e. to list on NASDAQ, companies must also have at least 450 round lot shareholders or ...

## Team
- Richard Uhlig (CEO and Founder)
- Benjamin Perry (President)
- Richard Bongo (Chief Financial Officer)
- James Croke (General Counsel)
- Dave MacLean (Chief Marketing Officer)
- Syed Ameen (Executive Vice President Corporate Strategy)
- Jeremy Williams (Chief Technology Officer)
- Chris Horacek (Deputy General Counsel)
- Kayla Wagner (Vice President of Product Management)
- Bryan Greene (Chief Operating Officer)

## Recent posts
- One Day Left to Invest! (2021-02-17T15:43:08Z)
- Offering Closing Soon (2021-02-16T15:34:09Z)
- One Week Left to Invest (2021-02-11T23:23:51Z)
- Quadrant Concussion Research in the News (2021-02-10T22:22:34Z)
- Offering Closing Soon! A Note from CEO Rich Uhlig (2021-02-05T21:36:23Z)
- Investment Closing Soon! (2021-02-02T20:16:58Z)
- Quadrant Partners with SUNY Upstate to Build New COVID-19 Lab in Buffalo! (2021-02-01T19:36:42Z)
- Quadrant and SUNY Upstate Project of the Year Award Update (2021-01-28T17:03:59Z)
- An Interview with Rich Uhlig: "RNA breakthroughs in autism, concussions, and COVID-19" (2021-01-12T17:32:52Z)
- MedTech salutes the Clarifi COVID-19 Saliva Swab as Project of theYear! (2021-01-01T18:07:27Z)
- SUNY Upstate Medical University to partner with New York Power Authority to test essential utility workers using the Clarifi COVID-19 saliva test (2020-12-30T17:33:27Z)
- Albany Airport Begins Offering the Clarifi COVID-19 Saliva Test to Arriving Passengers (2020-12-28T22:59:16Z)
- Investor Update from CEO Rich Uhlig (2020-12-16T21:17:39Z)
- FDA ranks Quadrant Covid-19 saliva test as most sensitive on market! (2020-12-09T22:07:31Z)
- Quadrant Biosciences Featured at Amazon Web Services Annual Conference (2020-12-07T18:48:06Z)

## Q&A
- Q: Couple of questions: - Says here that you raised $30M in total or around $24M in 2019. Your cash equivalent is $3.1M. That's an annualized $4.8M net burn rate (after revenues) since 2015 when the company was founded. That's an extremely high burn for not much R&D (since you are licensing the technology from Upstate Medical University and Penn State). Where is the money being spent on? - On your P&L 2018 had $90K in sales, but 2019 had $0. Why the sudden drop? - Also on your P&L salary and wages for 2019 was $1.9M. It states you have 40 employees which averages out to $47K/year in annual base salary. Something doesn't add up. Can you clarify? - I don't see any M.D. / Ph.D. on the executive team outside of Alexandar, but he's a bioinformatician and NOT a wet lab specialist which is needed for the spit test you are developing. Why is this? - $266M pre money seems extremely rich. What's the exit strategy here? I also did not see any total addressable market (bottoms up analysis) available for how much revenue the company can generate. Any details here? - I don't see anything in the deck that mentions insurance reimbursements and receiving approval for it. This is a huge deal, why hasn't it been shown?
  - A: Hi Richard, Great questions. While we did license the initial (pilot) technology from SUNY Upstate and the Penn State College of Medicine in 2015, we've spent the past 5 years doing clinical research alongside these institutions as well as several others (our NIH Phase II grant related to Autism Spectrum Disorder also includes Cincinnati Children’s Hospital, University of Missouri, and Texas Children’s Hospital). In addition to these institutions, we have several other clinical research sites within and outside the US. We now have more than 1,100 patients aged 18-83 months that are part of our ASD study which includes deeply phenotyped children who are either (i) diagnosed as ASD per DSM5 criteria, (ii) have non-ASD developmental delays, or (iii) are neurotypical. In addition to this work, we have (a) over 300 patients in our multi-center Parkinson’s Disease study, including patients clinically diagnosed as PD, those who have non-PD movement disorders and typically aging adults, (b) over 1,400 samples from patients in our concussion/TBI study and (c) several hundred geriatric patients in our fall-risk/early cognitive decline study (not to mention our work in Anorexia Nervosa). For each of our major areas of interest, we gather deep phenotypic data along with medical histories and demographic data and combine this with full-shotgun sequencing epigenetic data (about 8-10mm transcripts aligned to the human genome (miRNA, piRNA, circRNA, etc.) as well as the microbiome (bacteria, virus, archaea, phage, etc.); in a growing portion of our database, we have full exome sequencing data as well. More detail about our methodologies can be derived from the following published work titled “Validation of a Salivary RNA Test for Childhood Autism Spectrum Disorder” available here: https://www.frontiersin.org/articles/10.3389/fgene.2018.00534/full For our wet-lab work, we are closely partnered with the SUNY Molecular Analysis CORE facility and the faculty at SUNY Upstate Medical University (in fact, we’re down the hall from the CORE facility and typically use about 80% of their sequencing capacity). If you notice in our offering circular, the Research Foundation for the State University of New York is a major shareholder of Quadrant Biosciences. We have a similar research relationship with the Penn State College of Medicine. If you review our 14 peer-reviewed publications (available here: https://www.quadrantbiosciences.com/research/ ), you’ll better understand the number and breadth of MDs and PhDs that are part of our team at Quadrant. In December 2019, we sold over 1 million shares to sophisticated high-net worth individuals at a valuation of $222 million. Since then, we’ve achieved some major milestones, including the initiation of sales of Clarifi ASD (we received CLIA regulatory approval in late November): Clarifi ASD is now offered in more than 130 clinics in 30 states. Equally as significant, we received a Proprietary Laboratory Analyses (PLA) code from the American Medical Association on December 30, 2019 (this code is now active). As you know, our receipt of this PLA code is critical for both medical coding and reimbursement purposes. With over 600,000 US children a year experiencing developmental delays and nearly 65,000 with Autism Spectrum Disorder, our mission to help improve the lives of children and their families is quite significant. Lastly, while some of our payroll is expensed, about half is capitalized – please fee free to contact us directly if you are unfamiliar with GAAP in this regard. I hope I answered your questions – and I hope you choose to join us as an investor! With kind regards, Rich
- Q: The autism saliva test sounds exciting and surely adds value to the company--but I also know that a big part of the value of a company is the product pipeline. What, if anything, does Quadrant Biosciences have in the pipeline?
  - A: Hi Deb, We think that Clarifi ASD is very exciting too! This is game-changing technology that can improve the lives of millions of children and their families. Our research and development efforts use the same underlying technology - evaluating epigenetic molecules found in the saliva - for the rapid and early diagnosis of several other neurological conditions, including Parkinson's Disease and Concussion Injuries. Some of our peer-reviewed research in these areas include: The oral microbiome of early stage Parkinson’s disease and its relationship with functional measures of motor and non-motor function https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597068/ , and Comparison of serum and saliva miRNAs for identification and characterization of mTBI in adult mixed martial arts fighters https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314626/ . In short, we've got a very exciting product pipeline! Thank you for the excellent question. Sincerely, Rich
- Q: Hi, As an investor in previous round, What was the valuation of the company in the last round vs current round ? And why do we need more capital considering the capital accumulated from last round was supposed to give you a runway for sometime ? Is this just because of COVID-19 projects ? Whats happening with the original idea of the business that I signed up for
  - A: Thanks for your question Ashish. The company’s valuation is based on the number of outstanding shares of the company and the price per share most recently paid by investors. The price per share in our Regulation A offering was $3 share, and this is the price at which our valuation was calculated; as we have not since offered any shares the company’s valuation remains unchanged. Our current Regulation CF offering of convertible promissory notes with an interest rate of 6% per year and a stated maturity date of August 25, 2025. The notes will convert to common shares of the company at a 20% discount to the share price or equivalent, upon maturity or an earlier (i) "change of control" of the company, or a “qualified equity financing” by the company, as more fully described in the actual form of convertible note. The company’s “pre-Covid” business plan remains the same, but as you know the Covid pandemic resulted in our pivoting our efforts towards the development of our suite of Covid test products. Although the company has achieved some significant recent commercial success through the sale of its suite of Covid test products, the company’s management believes its epigenetic diagnostic products are central to the company’s long term prospects and that it is prudent, and in the company’s and shareholders’ best interest, for the company to continue to raise funds, so as to maintain sufficient liquidity to fund its ongoing businesses and operations. Sincerely, Richard Bongo
- Q: Will I see a return on my investment soon?
- Q: Hello, Is there an intent of going public in the near future? If yes, can you provide an estimate time frame? Thanks
  - A: Hi Giancarlo, As you can likely intuit, this offering presages our intended public listing. As you may know, many of the requirements to offer securities in this Regulation A offering conform to the high standards of a public offering (i.e. financial statements audited by a PCAOB certified accounting firm); this offering will help us achieve other listing requirements as well (i.e. to list on NASDAQ, companies must also have at least 450 round lot shareholders or 2,200 total shareholders). Great question - I hope you choose to join us as an investor! Sincerely, Rich
- Q: I invested in your companyb5 years ago. Now you are shutting down. I want my investment back or I will pursue it legally and file for treble damages
- Q: It looks like Quadrant Biosciences is bankrupt or insolvent. I would appreciate any update here from the company and WeFunder.
- Q: You have provided zero updates or information about the company. If you are bankrupt, please advise WeFunder, as the investors need to write off their investment interest.
  - A: Morning Elizabeth, I hope all is well. Quadrant is doing well, and we have been emailing individual investor updates quarterly. Please send me your email address, and I will verify that KoreConX, our Registrar, has your correct information. Thanks, Rich Bongo, CFO
- Q: Echoing a fellow investor's question, is there an update?
- Q: Hi, I’m just looking for an update of my investment
- Q: How do I register?
- Q: Are you going to start selling Clarifi COVID-19 Test Kits directly to individual customers?
- Q: I invested. When do i receive updates, ? etc
- Q: How do I get information about Quadrant Biosciuences shares I purchased through Wefunder?
- Q: is it too lat invest in this product?